Improved quality of life and pain relief in mature horses with osteoarthritis after oral transmucosal cannabidiol oil administration as part of an analgesic regimen.
Authors: Interlandi Claudia, Tabbì Marco, Di Pietro Simona, D'Angelo Fabiola, Costa Giovanna L, Arfuso Francesca, Giudice Elisabetta, Licata Patrizia, Macrì Daniele, Crupi Rosalia, Gugliandolo Enrico
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Osteoarthritis management in mature horses remains challenging, and conventional analgesics alone may not provide optimal pain relief in all cases. This randomised controlled trial investigated whether oral transmucosal cannabidiol (CBD) oil at 0.03 mg/kg daily for 14 days could augment standard phenylbutazone therapy in 20 horses with mild joint disease, measuring effects through clinical parameters, oxidative stress markers, and the Horse Chronic Pain Scale (HCPS). Whilst both treatment groups improved on phenylbutazone, the CBD-supplemented group demonstrated substantially greater pain relief, with median HCPS scores of 3 (range 2–4) compared to 7 (range 4–10) in controls, alongside significant reductions in heart rate, respiratory rate, white blood cell counts, and lipid peroxidation markers—indicating decreased systemic inflammation and oxidative stress. These findings suggest that CBD may offer a valuable adjunctive tool within multimodal analgesia protocols, particularly where conventional NSAIDs alone provide insufficient comfort, though practitioners should note the modest sample size and consider CBD's variable bioavailability and legal status across different jurisdictions when integrating it into clinical practice.
Read the full abstract on PubMed
Practical Takeaways
- •CBD oil supplementation can meaningfully reduce pain scores in arthritic horses beyond what conventional NSAIDs alone achieve—consider as adjunct to phenylbutazone in chronic cases
- •Monitor vital signs (heart rate, respiratory rate) in painful horses, as CBD showed measurable improvements; oxidative stress reduction suggests anti-inflammatory benefit
- •At 0.03 mg/kg daily for 14 days, oral CBD appears safe and well-tolerated with no adverse effects reported—reasonable addition to existing pain management protocols
Key Findings
- •CBD group showed significantly lower Horse Chronic Pain Scale scores (median 3, range 2-4) compared to control group (median 7, range 4-10) after 14 days of treatment
- •CBD administration reduced heart rate, respiratory rate, white blood cell count, and oxidative stress markers (malondialdehyde) compared to phenylbutazone alone
- •Both groups showed pain reduction with phenylbutazone, but CBD addition provided superior analgesia without reported adverse effects
- •CBD-hemp oil formulation (0.03 mg/kg daily) was well-tolerated as adjunctive therapy to conventional analgesic protocols